Specific Action of the Lipoxygenase Pathway in Mediating Angiotensin II–induced Aldosterone Synthesis in Isolated Adrenal Glomerulosa Cells

Jerry L. Nadler, Rama Natarajan, and Naftali Stern
Sections of Endocrinology, University of Southern California/Los Angeles County Medical Center, Los Angeles, California 90033; Sepulveda Veterans Administration Medical Center, UCLA-San Fernando Valley Program, Sepulveda, California 91343

Abstract
Angiotensin II (AII) in adrenal glomerulosa cells activates phospholipase C resulting in the formation of inositol phosphates and diacylglycerol rich in arachidonic acid (AA). Although glomerulosa cells can metabolize AA via cyclooxygenase (CO), this pathway plays little role in aldosterone synthesis. Recent evidence suggests that the lipoxygenase (LO) pathway may be important for hormonal secretion in endocrine tissues such as the islet of Langerhans. However, the capacity of the glomerulosa cell to synthesize LO products and their role in aldosterone secretion is not known. To study this, the effect of nonselective and selective LO inhibitors on AII, ACTH, and potassium-induced aldosterone secretion and LO product formation was evaluated in isolated rat glomerulosa cells. BW755c, a nonselective LO inhibitor dose dependently reduced the AII-stimulated level of aldosterone without altering AII binding (91 ± 6 to 36 ± 4 ng/10^6 cells/h 10^{-4} M, P < 0.001). The same effect was observed with another nonselective LO blocker, phenidone, and a more selective 12-LO inhibitor, Baicalein. In contrast, U-60257, a selective 5-LO inhibitor did not change the AII-stimulated levels of aldosterone (208 ± 11% control, AII 10^{-9} M vs. 222 ± 38%, AII + U-60257). The LO blockers action was specific for AII since neither BW755c nor phenidone altered ACTH or K^+–induced aldosterone secretion. All stimulated the formation of the 12-LO product 12-hydroxyicosatetraenoic acid (12-HETE) as measured by ultraviolet detection and HPLC in AA loaded cells and by a specific RIA in unlabeled cells (501 ± 50 to 990 ± 10 ng/10^5 cells, P < 0.02). BW755c prevented the AII-mediated rise in 12-HETE formation. In contrast, neither ACTH nor K^+ increased 12-HETE levels. The addition of 12-HETE or its unstable precursor 12-HPETE (10^{-4} or 10^{-8} M) completely restored AII action during LO blockade. AII also produced an increase in 15-HETE formation, but the 15-LO products had no effect on aldosterone secretion. These studies suggest that the 12-LO pathway plays a key role as a new specific mediator of AII-induced aldosterone secretion.

Introduction
Angiotensin II (AII),^1 potassium (K^+), and ACTH are the major stimulators of aldosterone synthesis in vitro and in man (1–3) All three agonists activate the calcium messenger system, however, only AII induces the hydrolysis of phosphoinositides and releases intracellular calcium (4–6). After binding to its receptor, AII activates phospholipase C, which induces the formation of diacylglycerol and the release of arachidonic acid (AA) (7). The adrenal glomerulosa cell has been shown to metabolize AA via the cyclooxygenase (CO) pathway to prostaglandins E_2 and I_2 (8–10). However, considerable evidence suggests that the CO pathway is not involved in basal or AII-mediated aldosterone production (10–11).

Recent studies in rat pancreatic islets have shown that the lipoxygenase (LO) products of AA, such as 12 hydroxyeicosatetraenoic acid (12-HPETE) are important mediators of glucose-induced insulin secretion (12, 13). However, the capacity of the adrenal glomerulosa cell to synthesize LO products and their role in aldosterone synthesis is not known. We have evaluated the effect of AII, K^+, and ACTH on LO product formation in isolated rat adrenal glomerulosa cells. In addition, we have studied the functional role of LO pathway activation with the use of selective CO and LO inhibitors. The results suggest that the 12-LO pathway plays a key role in mediating AII-induced aldosterone synthesis.

Methods
Preparation of isolated rat adrenal glomerulosa cells. The cells were freshly prepared using the method of Williams et al. (14). Male Sprague-Dawley rats (200–225 g) were decapitated and the adrenals removed and trimmed of fat and placed in normal saline. Capsules were separated by gross dissection and incubated with collagenase (3.7 mg/ml) and deoxyribonuclease (0.05 mg/ml) in a modified Krebs-Ringer bicarbonate buffer (KRBB) containing 4% bovine serum albumin (BSA, Pentex Fraction V, fatty acid free) essential and nonessential amino acids, 1-g-glutamine and glucose for 50 min in a Dubonoff metabolic shaker under 95% O_2, 5% CO_2. The cells were then mechanically separated by gentle pipetting and filtered through a gauze mesh. The suspension was spun at 100 g and washed three times with the KRBB and the glomerulosa cells were resuspended in the same buffer solution (K^+ 3.7 meq/liter) to yield ~150,000 cells per ml. The viability of the cells was 95% as determined using trypsin blue exclusion.

Incubation of rat glomerulosa cells. The cell suspension in 2 ml of KRBB buffer with 4% BSA was incubated in the presence or absence of the various test compounds in a metabolic shaker for 60 min at 37°C under a 95% O_2/5% CO_2 atmosphere. The cells were incubated with graded doses of AII, ACTH, or K^+ (2 × 10^{-11} to 2 × 10^{-8} M, 1 × 10^{-11} to 1 × 10^{-8} M, and 3.7 to 10.7 meq/liter, respectively) either alone or with various AA inhibitors. The inhibitors used were: BW755c (3 amino-m-trifluoromethyl-phenyl-2-pyrazoline 10^{-7}, 10^{-4} M), Burroughs Wellcome Co., Beckenham, Kent, UK) or phenidone (10^{-6} M, Sigma) both nonselective LO inhibitors, baicalein (10^{-6} M BioMol Research Laboratories, Philadelphia, PA) a more selective 12 LO inhibitor (15), meclofenamate (10^{-3} M, Sigma Chemical Co.,

1. Abbreviations used in this paper: AA, arachidonic acid; AII, angiotensin II; CO, cyclooxygenase; ETYA, eicosatetraenoic acid; LO, lipoxygenase; LTBs, leukotriene B_2; NGDA, nordihydroguaiaretic acid; 12-HPETE, 12 hydroxyeicosatetraenoic acid.
tetraenoic (Piriprost, & French, (2-diethylaminoethyl-2, ethanol. Similar with cubations to MM, attached with BSA and ethanol. M). The incubation of 150 mM was used and washes 20,000 and BSA. The incubation of 10-9 M was added, then centrifuged 20,000 min. The initial solvent mixture was 10-4 M, was added, and incubation with 15-HETE elutes on basal 5-LO products on basal 12-HETE formation was used to quantify endogenous 12-HETE formed in the basal state and after agonist stimulation. We used the specific antiseria provided by Advanced Magnetics, Inc. (Boston, MA) in a working titer of 2 x 10^3 dilution giving a B.S. of 54%. The cross-reactivity of this antiserum is: 12(S)-HETE 100%, 12(R)-HETE < 0.01%, 15-HETE 0.3%, 5-HETE 0.2%, thromboxane B2 (TXB2) = 0.1%, PGE2, 0.1%, 16 keto prostacycline 1α (PGF1α) 0.1%, leukotriene B4 (LTB4) 0.1%, arachidonic acid 0.1%, 8,15 and 5,15 diHETE 0.1% and 8,9, and 11-HETE; all < 0.01%. For the assay 100 μl of the appropriate dried fraction was incubated with antibody (100 μl) and authentic [3H]12-HETE tracer (4,000 cpm, New England Nuclear) in a phosphate buffer solution, pH 8.5 overnight at 4°C. Separation of bound from free was achieved by the addition of 700 μl of dextran-coated charcoal. Nonspecific binding is < 6% with an assay blank of 8 pg/ml. The sensitivity of the method is 10 pg/ml with an intraassay variation of 8%. All control and experimental samples were run in the same assay. Validation procedures included the assay of known added amounts of standard and variable amounts of extract (r = 0.95). In addition, sample values gave an excellent correlation (r = 0.91; P < 0.01) when assessed using the well characterized independent 12-HETE antiseria kindly provided by Dr. L. Levine, Brandeis University (20). All samples for the RIA were stored in the dark under nitrogen at ~70°C until assay. 15-HETE was assayed using specific antiseria provided by Advanced Magnetics Inc., in a working titer of 1:700 with binding at Bo of 56%. It has low cross-reactivity: 5-HETE 0.1%, 12-HETE 0.5%, 5,15 diHETE 1%, 8,15 diHETE 1%, arachidonic acid, PGB2, PGE2, PGF1α, TXB2, all 0.1%. The assay used authentic [3H]15-HETE tracer (4,000 cpm). The assay technique is the same as for the 12-HETE method. Nonspecific binding is < 7% with an assay blank of 6 pg/ml. The sensitivity is 10 pg/ml with an interassay variation of 10%. All control and experimental samples are run in the same assay. Assay of known amounts of standard gives an excellent correlation with calculated (r = 0.92).

Aldosterone measurement. At the conclusion of each incubation a 200-μl aliquot of the cell suspension was removed and extracted with methylene chloride (1:15 vol/vol) and assayed for aldosterone by RIA.
using a highly specific antibody obtained from Endocrine Sciences (Tarzana, CA). Cross-reactivity of this antiserum with corticosterone, deoxycorticosterone, 18 hydroxycorticosterone, progesterone, 17-OH progesterone is < 0.01%. This assay technique correlated well with a previously described method using chromatography (r = 0.99, slope = 0.98, n = 55) (21).

Corticosterone levels were measured by RIA with a highly specific antibody supplied by Endocrine Sciences.

Data analysis. To compare basal with experimental values for aldosterone and 12-HETE a Student’s t test was used for nonpaired values. Data analysis was performed on a CLINFO Computer System (GCRC RR-43). Binding data was analyzed using a version of LIGAND adopted for an Apple IIe computer.

Results

Effect of LO inhibition on aldosterone synthesis. The nonselective LO inhibitor, BW755c (10^-4 M) markedly reduced the AII-stimulated secretion of aldosterone (Fig. 1 a). BW755c decreased the overall mean maximal AII stimulated aldosterone secretion from 91±6 to 36±4 ng/10^6 per h (n = 12, P < 0.001). Similarly BW755c reduced AII-mediated secretion of corticosterone (4.6±0.06 to 2.8±0.4 μg/10^6 cells per h, n = 3, P < 0.002) while the secretion rate was not significantly different than baseline (2.6±0.02 μg/10^6 cells). The inhibitory effect was dose dependent with significant reduction of AII-induced aldosterone synthesis by concentrations of BW755c starting at 10^-7 M (Fig. 1 b). In several experiments (7/12) BW755c at 10^-4 M also reduced basal aldosterone secretion (42±5 to 30±3 ng/10^6 cells per h, n = 7, P < 0.01). In contrast, BW755c did not alter the sensitivity or peak secretion rate of aldosterone incubated with graded doses of ACTH (Fig. 2) or K+ (Fig. 3). Another LO inhibitor, phenidone (10^-4 M) significantly reduced AII-stimulated aldosterone secretion (29±1 basal to 67±2 AII 10^-9 M vs. 50±2 ng/10^6 cells/hour AII + phenidone n = 6, P < 0.05 vs. AII alone). However, pheni-

![Figure 1](image1.png)

**Figure 1.** (a) Angiotensin II (AII) stimulated aldosterone secretion in the absence (--- ○ ---) and presence of the lipoygenase inhibitor BW755c (10^-4 M) (----- ○ -----). Results are the mean±SE or triplicate determinations (n = 3) in 1 of 12 such experiments. (b) Effect of incremental concentration of BW755c on AII (10^-9 M) mediated aldosterone secretion. Results are expressed as mean percent±SEM of AII-stimulated aldosterone levels (n = 6), from two separate experiments. Dotted line represents basal aldosterone secretion (0.8±0.1 ng/10^6 cells per h). AII in the absence of inhibitor produced levels of aldosterone at 8.3±0.3 ng/10^6 cells per h.

![Figure 2](image2.png)

**Figure 2.** Effect of ACTH on aldosterone secretion in the absence and presence of BW755c (10^-4 M). Results are the mean±SE of triplicate determinations (n = 3) in one of three similar experiments.

done did not alter K+ induced aldosterone release (105±12 vs. 87±11 ng/10^6 cells per h, 5.7 meq and 109±18 vs. 104±17, 8.7 meq, n = 6, P = NS for K+ alone vs. K+ + phenidone, respectively).

Since BW755c can also block the CO pathway, a selective CO blocker meclofenamate was studied to determine whether the effects of BW755c were due to CO inhibition. However, as shown in Table I, even a high concentration of meclofenamate (10^-3 M) did not prevent AII-induced aldosterone synthesis.

Baicalein, a more selective 12-LO inhibitor with little CO inhibitory effects was also studied. This more specific agent also reduced AII-mediated aldosterone secretion (10±0.5 basal

![Figure 3](image3.png)

**Figure 3.** Effect of potassium (K+, millimoles per liter) on aldosterone synthesis in the absence or presence of BW755c (10^-4 M). Results are the mean±SE of triplicate determinations (n = 3) in one of three similar experiments.
Table I. Effects of Meflofenamate and U60257 on AII-stimulated Aldosterone Secretion

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Meflofenamate</th>
<th>U60257</th>
</tr>
</thead>
<tbody>
<tr>
<td>KRBG alone</td>
<td>98±8</td>
<td>100±16%</td>
<td>100±8%</td>
</tr>
<tr>
<td>AII, 10⁻⁹ M</td>
<td>208±11%*</td>
<td>210±10%*</td>
<td>222±38%*</td>
</tr>
<tr>
<td>AII, 10⁻⁸ M</td>
<td>255±15%*</td>
<td>287±48%*</td>
<td>232±15%*</td>
</tr>
</tbody>
</table>

Results are in percentage of basal as the mean±SEM of six to nine determinations from two to three separate experiments. Basal secretion was 21±2 ng/10⁶ cells/h.

* P < 0.01.

vs. 32±2 ng/10⁶ cells per h. AII 10⁻⁹ M vs. 20±2 AII + baicalein 10⁻⁶ M, n = 6, P < 0.02 AII vs. AII + baicalein). The steroidogenic inhibitory actions were also associated with a reduction in 12-HETE formation (120±2% control AII vs. 78±5% AII + baicalein, P < 0.01).

To examine the role of the 5-LO pathway in AII action, a selective 5-LO inhibitor U60, 257 was studied. As shown in Table I, this highly selective 5-LO inhibitor did not attenuate AII stimulatory effects on aldosterone synthesis, suggesting that BW755c, phenidone, and baicalein are not acting via 5-LO inhibition to block AII effects.

Effect of LO inhibition on [³²P]AII binding to glomerulosa membranes. Since LO inhibition selectively blocked all mediated aldosterone synthesis, the effect of the LO inhibitor BW755c on AII binding to glomerulosa cell membranes was studied. Mean AII receptor concentration was similar in control membranes and in those co-incubated with BW755c, respectively, [1.170±74 fmol/mg protein (n = 5) and 1.220±60, n = 2]. Similarly, BW755c did not alter receptor affinity (Kᵦ), (1.50±0.2 × 10⁹ M⁻¹ and 1.75±0.2 × 10⁹ M⁻¹ control and BW755c treated membranes, respectively).

Effect of AII, ACTH, and K⁺ on HETE formation. AII (10⁻⁹ M) stimulated the formation of immunoreactive 12-HETE (Fig. 4) (501±50 to 990±10 pg/10⁵ cells P < 0.02). In addition, BW755c reduced the stimulated level back to the control level (Fig. 4). AII also slightly stimulated immunoreactive 15-HETE levels (756±80 to 1,050±90 pg/10⁵ cells, n = 4, P < 0.05). Similarly, in cells prelabeled with 99% pure AA, AII stimulated predominately 12-HETE as revealed by ultraviolet detection at 235 nm in a sensitive reverse-phase HPLC system (Fig. 5, a–c). The peak heights shown at the same attenuation setting reveal the marked stimulation of peaks co-migrating with 12-HETE and to a lesser extent 15-HETE. This was also confirmed by comigration with the authentic [³H]12-HETE and [³H]15-HETE in the same sample. Both the 12 and 15 HETE peaks showed an ultraviolet maximum at 235 nm. The addition of BW755c to the incubation greatly reduced the peak heights corresponding to the HETES and gave heights of 12 and 15 HETE similar to the basal (Fig. 5 c). AA alone (not shown) incubated with medium alone or boiled cells gave no major peaks in the region of 12-HETE or 15-HETE suggesting...
**Table II. Effect of ACTH and K⁺ on Immunoreactive 12-HETE Formation**

<table>
<thead>
<tr>
<th>Incubation condition</th>
<th>ACTH 10⁻⁹ M</th>
<th>10⁻⁸ M</th>
<th>K⁺ 5.7</th>
<th>8.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% control</td>
<td>100±10 (6)</td>
<td>78±13* (5)</td>
<td>90±15 (5)</td>
<td>72±11* (3)</td>
</tr>
</tbody>
</table>

Values are shown as percent of control (mean±SD).

* P < 0.01 vs. control values using a nonpaired t test adjusted for unequal variance using a CLINFO computer system. Parentheses include the number of observations.

no major nonenzymatic conversion of AA to 12 or 15-HETE. In contrast, ACTH and K⁺ did not stimulate the formation of immunoreactive 12-HETE. Surprisingly, these agents tended to lower 12-HETE levels compared with the control (Table II).

To evaluate whether 12-HETE formation is via a cytochrome P450 epoxygenase enzyme, the effect of metyrapone and SKF525A on 12-HETE formation was studied. At 5 × 10⁻⁵ M concentration metyrapone and SKF525A similarly reduced aldosterone secretion (1.4±3 to 0.4±0.1 and 0.46±0.1 ng/10⁶ cells per h, respectively, n = 4, P < 0.01). However, neither inhibitor altered 12-HETE levels (517±41 basal vs. 651±37 vs. 739±89 pg/10⁵ cells, respectively, n = 4, P > 0.1).

**Effect of 12 and 15 LO products on aldosterone secretion.**

To further evaluate the functional role of the 12-LO pathway for All action, the effect of 12-HETE and its unstable precursor 12-HPETE on restoring All stimulation of aldosterone during BW755c treatment was studied. 12-HETE in concentrations as low as 10⁻¹⁰ M partially restored All action, while concentrations of 10⁻⁸ and 10⁻⁹ M completely restored the stimulatory effects of All during LO blockade (Fig. 6). Similarly, 12-HPETE (10⁻⁸ M) restored the All-mediated aldosterone levels (240±20% basal, All 10⁻⁹ M alone vs. 95±19%, All + BW755c vs. 210±46%, All + BW755c + 12-HPETE). 12-HPETE also directly stimulated aldosterone secretion (100±5% basal to 133±8%, 10⁻⁹ M, n = 6, P < 0.02 and 163±11% 10⁻⁸ M, n = 6, P < 0.01 vs. basal). In marked contrast, neither 15-HETE nor 15-HPETE altered aldosterone secretion (100±6% basal vs. 107±11, 15 HETE, 10⁻⁸ M and 120±8% 10⁻⁸ M, 15-HPETE both P < 0.3, n = 6).

**Discussion**

Increasing evidence suggests that All in adrenal glomerulosa cells and in isolated vascular smooth muscle activates phospholipase C, resulting in the formation of inositol phosphates and diacylglycerides (4, 22–24). Although, the turnover of inositol phosphate is rapid and transient, recent studies indicate a longer, more sustained formation of diacylglycerol that may explain the sustained action of All despite the return of intracellular Ca²⁺ to basal levels (4, 24). Despite the evidence that diacylglycerol is rich in AA and All can increase the release of AA in adrenal glomerulosa cells, the precise role of this fatty acid and its derived products in steroidogenesis has not been clarified.

Previous studies have shown that the adrenal glomerulosa can synthesize CO products of AA such as PG₁₂ and PGₑ₂ (8–11). However, considerable evidence suggests that these PGs do not play a role in steroidogenesis since most studies indicate that All, ACTH, and K⁺ do not stimulate their formation, nor do CO blockers prevent All-induced aldosterone synthesis (8, 11, 25, 26). Several reports have shown that indomethacin can alter aldosterone synthesis (10, 27, 28). However, this has not been a consistent finding (8, 11, 25, 26) and the current study as well as others using other more specific CO blockers such as meclofenamate and U-51605 show no inhibition of All induced aldosterone formation (9, 28, 29). This suggests that indomethacin has nonspecific effects which can alter steroidogenesis.

The current investigation is the first study to show that isolated adrenal glomerulosa cells produce LO products from both endogenous and exogenously derived AA. The major product formed, 12-HETE, was detected using two independent methods, UV detection during HPLC and a specific RIA. The results suggest that 12-LO activation may be a key step in All-induced aldosterone synthesis. This is supported by several observations including: (a) All, but not ACTH or K⁺ stimulates 12-HETE formation; (b) three distinct LO inhibitors that prevent 12-HETE formation selectively block All induced aldosterone synthesis; (c) The inhibitory effects of LO antagonists are not via interference with All binding to its receptor; and (d) The addition of 12-HETE and 12-HPETE restores the All stimulatory effects during LO inhibition.

In this study two nonselective LO inhibitors, BW755c and phenidone, and a more selective 12-LO inhibitor baicalein blocked All-induced aldosterone formation. We did not use several other reported LO inhibitors such as nordihydroguanisartiac acid (NDGA) and eicosatetraenoic acid since these agents, unlike BW755c, have potent effects on guanylate cyclase (30). In addition NDGA and ETYA can nonspecifically alter contractile responses independent of effects on LO enzyme inhibition (31). Also, NDGA at lower doses is a more
potent inhibitor of 5-LO activity (32). BW755c did not appear to be toxic based on the normal appearance of the cells, the dose-dependent inhibitory actions on AA and its lack of effect on K+ and ACTH-induced aldosterone release. Similarly, BW755c did not appear to be acting as a Ca2+ channel blocker since K+ induced aldosterone formation was not altered. This is also supported by the study by Rasmussen and co-workers who showed that BW755c prevented AI-induced aldosterone formation without altering AI mediated Ca2+ flux (26).

In contrast to the effect of BW755c, phenidone, and baicalein, a specific 5-LO inhibitor U-60257 at doses that have been shown to markedly inhibit 5-LO activation (16) in other cell types, did not prevent AI-induced aldosterone production. These results suggest that the 12 and not the 5-LO pathway is involved in AI-mediated steroidogenesis.

15-HETE is also synthesized in the glomerulosa cells in the basal state and in response to AI. However, the magnitude of 15-HETE stimulation by AI is less than for 12-HETE and neither 15-HPETE nor 15-HETE alter aldosterone synthesis. This suggests that the 15-LO pathway is not primarily involved in AI-mediated steroidogenesis. However, additional studies will be required to determine whether 15-HETE is involved in other actions of AI, such as glomerulosa cell mitogenic activity and growth.

The glomerulosa cell preparation used in the current study may be contaminated with up to 5% fasciculata cells. However, recent evidence suggests that isolated rat fasciculata cells do not synthesize 12-HETE but only the 5-LO derived products such as 5-HETE and LT5B2 (33). In addition, in the rat one would not expect a fasciculata-derived product to be stimulated by AI. Therefore, the source of 12-HETE is most likely from 12-HPETE synthesized by the glomerulosa cells.

The mechanism of 12-LO pathway mediated aldosterone synthesis cannot be determined from this study. Since LO blockade diminishes both the aldosterone and corticosterone response to AI, the effect appears to modulate the early pathway of aldosterone synthesis. Some evidence suggests that several AA metabolites including the HETEs can activate protein kinase C (34), while other studies show that 12-HETE can induce vascular smooth muscle migration via changes in Ca2+ flux (35). A very recent study also suggests that AA itself in Ca2+ free media can increase intracellular Ca2+ levels in rat islets of Langerhans (36). Additional studies using specific inhibitors of the protein kinase C and Ca2+ messenger systems will be needed to clarify these effects. However, since diacylglycerol is potentially a major source of AA for LO activation, 12-LO products formed most likely function to maintain aldosterone synthesis during the sustained phase of action of AI. This is supported by the recent study showing that in a perifusion system BW755c inhibits AI-induced aldosterone synthesis only after 20 min (26).

Increasing evidence suggests that metabolism of AA via the LO or cytochrome P-450 epoxygenase pathway may produce important mediators of stimulus-secretion coupling in endocrine tissues such as the pituitary (37–39), gonad (40), and pancreatic islet (12, 13, 41). The current results now suggest that AA conversion to products of the 12-LO pathway is a key step in AI induced action in the adrenal gland. Our results showing no inhibition of 12-HETE with two structurally distinct cytochrome P450 inhibitors suggests that 12-HETE formation in the rat adrenal glomerulosa cell is not via the P450 epoxygenase system described by others in the kidney and liver (42–44). However, additional studies will be needed to fully clarify whether other AA metabolites such as epoxides play any role in aldosterone synthesis.

In summary, in isolated glomerulosa cells, AI predominately stimulates the formation of the 12-LO product, 12-HETE, which functions as an important mediator of AI-induced aldosterone formation. The synthesis of 12-HETE is specifically linked to AI, since neither K+ or ACTH enhance 12-HETE formation. Since AI is a major regulator of both aldosterone synthesis and vascular smooth muscle tone, these results may form the basis for a new understanding of pathologic states in man associated with altered levels or action of angiotensin II.

Acknowledgments

The authors thank Ms. Denise Walters for preparation of the manuscript and S. Goodson and Gerard Jensen for their technical assistance. In addition we thank S. Moncada of the Burroughs Wellcome Co. for BW755C and M. Bach of Upjohn for U60, 257.

This research was supported in part by the American Heart Association, Los Angeles Affiliate (841 G1-1 and 831 G1-1) and the Veterans Administration (Dr. Stern). Dr. Nadler is the recipient of NIH Clinical Investigator Award HL01496.

References


dative metabolism


Lipoxygenase Pathway and Angiotensin II-induced Aldosterone Synthesis